Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (2)
P 2 (1)

Trial Status

Recruiting3
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07559695Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

NCT06440135Phase 1Recruiting

Ziftomenib Maintenance Post Allo-HCT

NCT06052813Phase 1Active Not Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

NCT07101497Phase 2Recruiting

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

Showing all 4 trials

Research Network

Activity Timeline